Stable liposomal formulations for ocular drug delivery

A kind of liposome preparation, the technology of liposome, be used in the field of liposome preparation

Active Publication Date: 2019-08-23
NANYANG TECH UNIV +1
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, a substantial portion of the drug enters the circulation via the conjunctival sac causing undesired systemic side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stable liposomal formulations for ocular drug delivery
  • Stable liposomal formulations for ocular drug delivery
  • Stable liposomal formulations for ocular drug delivery

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Preparation of large unilamellar vesicles (LUV) for drug release studies

[0028] A thin-film hydration technique was used to formulate latanoprost-loaded POPC liposomes for drug release rates. Briefly, POPC was weighed and dissolved in a chloroform:methanol (2:1 v / v) solvent mixture. Latanoprost (2 mg / ml stock solution in acetonitrile) was added to the lipid solvent mixture at a drug:lipid molar ratio of 0.175:1 and maintained at 40°C. The solvent mixture was added to a round bottom flask in a rotary evaporator attached to a water bath maintained at 40°C. The flask was rotated at 100 rpm for 1 hour under low pressure to remove solvent, thereby forming a thin drug-loaded lipid film. Isotonic phosphate buffered saline (PBS) (150 mM, pH 5.5) was added to this membrane to form multilamellar vesicles (MLV). These MLVs were extruded 10 times through polycarbonate filters (0.2 μm-0.08 μm). This extrusion resulted in the formation of LUVs with diameters having...

Embodiment 2

[0029] Example 2: Preparation of LUVs for Drug Stability Studies

[0030] Drug-loaded LUVs were also prepared for stability studies. POPC was dissolved in PBC (at pH 6.7) and kept stirring at room temperature for 2 hours to form MLV. These MLVs were extruded 3-5 times using 3 polycarbonate films of 80 nM size stacked together on a benchtop extruder to form POPC LUVs. Latanoprost was dissolved in ethanol, and the resulting solution (in a round bottom flask maintained in a water bath at 50°C) was dried under a stream of nitrogen to form a thin drug film. The drug film was hydrated with the POPC LUVs at room temperature for 2-3 hours until no oil droplets were observed on the flask walls. A latanoprost:POPC molar ratio of 0.175:1 was used to prepare drug-loaded LUVs. Latanoprost-loaded POPC LUVs were sterile filtered at room temperature using a 0.2 μm syringe filter and stored at 4°C until analysis. A similar method was used to prepare eggPC liposomes loaded with latanopros...

Embodiment 3

[0031] Example 3: Characterization of drug-loaded POPC liposomes

[0032] Drug release studies were performed by dialyzing latanoprost-loaded POPC liposomes prepared as described in Example 1 above against PBS (at pH 7.4) and measuring The amount of latanoprost released. The results are shown in figure 1 middle. Over a period of 28 days, approximately 65% ​​of latanoprost was released from the latanoprost-loaded POPC liposomes in a time-dependent manner.

[0033] The physical characteristics of these latanoprost-loaded POPC liposomes were measured essentially as described in International Application Publication No. 2012 / 021107 by Venkatraman et al., the contents of which are incorporated herein in their entirety as as reference data.

[0034] The stability of latanoprost-loaded POPC liposomes prepared as described in Example 2 above was measured and compared to similar latanoprost-loaded eggPC liposomes. The stability of these liposomes stored at 4°C was assessed over a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

A stable liposomal formulation for ophthalmic drug delivery. The formulation comprises a liposome comprising at least one lipid bilayer comprising lecithin; and prostaglandin F encapsulated within the liposome 2α . Also provided herein is a method of treating eye diseases with the formulation.

Description

technical field [0001] The present invention relates to stable liposomal formulations for ophthalmic drug delivery. Background technique [0002] Intraocular pressure (IOP) in the eye is maintained by a continuous flow of aqueous humor produced by the ciliary body. Excess fluid drains out of the eye through the trabecular meshwork of the sclera. If the outflow is blocked, aqueous humor builds up inside the eye causing increased IOP and ocular hypertension. Ocular hypertension can damage the optic nerve, leading to optic neuropathy and irreversible visual impairment. The condition, known as glaucoma, affects more than 60 million people worldwide and is the second leading cause of blindness. Increased IOP is a key modifiable risk factor for glaucoma. [0003] Traditional treatments for ocular hypertension and glaucoma include eye surgery and topical eye drops. These treatment modalities have drawbacks. For example, not all patients are candidates for eye surgery. Furthe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/127A61K31/5575A61K47/24A61P27/06
CPCA61K9/0048A61K9/127A61K31/216A61K31/5575A61P27/00A61P27/02A61P27/06
Inventor 苏布拉马尼亚·文卡特拉曼贾亚加内什·V·纳塔拉詹蒂娜·豪登弗雷迪·博埃
Owner NANYANG TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap